Noul Unveils Advanced AI-Driven Cervical Cancer Screening Technology at NVIDIA GTC 2025

Noul Unveils AI-Powered Cervical Cancer Screening Technology

At the NVIDIA GTC 2025, held in San Jose, California, Noul Co., Ltd., a South Korean medical AI innovator, made headlines by presenting its cutting-edge AI-based diagnostic platform, miLab™ CER. This event is renowned for showcasing advancements in artificial intelligence and its application across various sectors, including healthcare.

The centerpiece of Noul's presentation was a poster titled "Bridging Medical Gaps from Malaria to Cancer: On-Device AI Diagnostic Solutions Powered by NVIDIA Jetson." This initiative aims to enhance diagnostic accessibility in healthcare, especially for underserved populations worldwide.

A Solution to Global Challenges

Cervical cancer remains a pressing global health issue, ranking as the third leading cause of cancer-related mortality among women. Access to screening is often limited, particularly in low- to middle-income countries and even within centralized healthcare systems of developed regions. Noul's miLab™ platform addresses these challenges.

David Lim, CEO of Noul, expressed pride in showcasing this pioneering diagnostic solution, emphasizing the miLab™ technology's capability to deliver real-time diagnostics without relying on cloud-based systems. The device's independence from cloud infrastructure is revolutionary, ensuring that healthcare providers can perform diagnostics in various settings, from remote villages to high-tech hospitals.

The miLab™ Platform

miLab™ is the world's first fully automated digital microscope designed for quick and efficient on-site diagnostics. It incorporates advanced elements such as automated sample staining, digital imaging, and embedded deep learning, all of which contribute to an AI-driven result analysis, providing diagnosis results in a mere 15 minutes. Thanks to its integration with NVIDIA Jetson technology, the platform achieves remarkable AI inference performance tailored for widespread applications across numerous diseases.

Notably, miLab™ CER, the specialized cervical cancer screening solution, gained a prestigious mention in the 2024 WHO-UNITAID report as one of the top three global diagnostic products, ranking alongside offerings from established healthcare giants Roche and Hologic. This recognition underscores Noul's commitment to innovation in healthcare technology.

Joining the NVIDIA HCLS Ecosystem

With this presentation, Noul has become a member of the NVIDIA Healthcare & Life Sciences (HCLS) partner ecosystem. This collaboration marks a significant step towards leveraging artificial intelligence to improve healthcare outcomes globally. The company aims to form partnerships that enhance healthcare delivery and make diagnostics more globally accessible.

The GTC 2025 event, attended by over 25,000 participants in person and more than 300,000 online, serves as a platform for leaders in innovation to share their insights into the future of technology and its implications across various domains. The keynote address from NVIDIA’s founder and CEO, Jensen Huang, emphasized the transformative potential of AI in various industries, reiterating its relevance in the field of healthcare.

About Noul Co., Ltd.

Noul Co., Ltd. was established in December 2015 with the mission to tackle global health challenges through innovative AI technology. Dedicated to enhancing blood and cancer diagnostics, the company has achieved significant milestones with miLab™, which provides lab-level precision diagnostics rapidly at the point of care. By automating the entire microscopy workflow, miLab™ assures timely and accurate results, supporting healthcare professionals in their diagnostics efforts.

Noul’s vision extends beyond mere product development; it aims to positively influence the lives of over one billion people by improving access to critical health services. With its expanding product lines and strong clinical evidence backing its innovations, miLab™ is currently operational in 18 countries, empowering healthcare institutions, pharmaceutical companies, and governments alike.

For more about their advancements and initiatives, visit Noul's official website.